Directory · DK
Biotechnology in Denmark
A register of firms and the professionals working at them in the Biotechnology sector based in Denmark. Browse the public index, then filter or export on Kipplo.
Companies
60 on file
Kementec Solutions A S
Kementec is a well-established, innovative, and service oriented company with more than 35 years of experience as a manufacturer and supplier of components to the industry and to researchers worldwide. Being a market leader in developing solutions for immunoassays, our continuous goal is to deliver sustainable products without compromising on quality, sensitivity and accuracy. Kementec’s ECO-TEK products offer the highest level of sustainability for manufacturing immunoassays with the following characteristics- Free of BSA Easing cross border paperwork & improving assay reproducibility - Free of NMP or other harmful organic solvents – 100% aqueous Reducing regulatory concerns - Free of toxic preservatives and hazardous stop solutions Improving work environments Our immunoassay solutions are eco-friendly, creating a healthy work environment and preserving natural resources, while helping our customers fulfill significant regulatory requirements. Kementec values long lasting business relationships and the success of our customers. We consider ourselves more as a trusted partner than as a general supplier. We understand the importance of being able to supply on time, the same high-quality products in every shipment and being the partner that can assist with needed solutions in every situation. This enables you to focus on what you do best - developing and manufacturing high quality immunoassays. Your partner all the way - 360°
11 to 50 staff
Xnos
xNOS is a biotechnology company that specializes in developing a multi-target therapeutic compound for treatment of sexual dysfunction in both women and men with type 1 and type 2 diabetes mellitus. The company was founded in 2016 and today has developed a novel target drug candidate Xoin® (xNOSniox). xNOS's comprehensive molecular expertise is expected to lead to a stream of future innovative commercial products. Nitric oxide technology is a key focus of xNOS's strategy. xNOS's technology base consists of validated and proprietary next-generation endothelial nitric oxide synthase (eNOS) activator therapies.
1 to 10 staff
Unilabs - Serving Pharma
Unilabs Serving Pharma is part of Unilabs, a European leader in laboratory services. With employees and more than 30+ years of critical contributions in more than clinical trials covering a vast number of therapeutic areas, Unilabs is a preferred partner for execution of clinical trials in Europe. Unilabs Serving Pharma business unit offers laboratory testing support for drug development from screening and drug candidate seeking, over pre-clinical trials & clinical trials phases to registration, and commercialization of precision medicine test in Europe and beyond. Unilabs Serving Pharma expertise include the following areas: Discovery bioanalysis, in vitro ADME and metabolism Regulated bioanalysis for small and large molecules, biologics and biomarkers Immunogenicity, PK/PD, efficacy and safety parameters Molecular diagnostics, incl Next Generation Sequencing Flow cytometry Histopathology and cellular pathology Medical imaging Precision medicine central testing and logistics Contact: servingpharma@unilabs.com or Phone:+45 3119 3199 (Peder Andersen, BD) Phone:+45 2543 4404 (Hans Christian Pedersen, BD)
10001+ staff
Bactiquant A S
BactiQuant is a combination of the words 'Bacteria' and 'Quantify', as that is what we do. We help you quantify the amount of bacteria in water! BactiQuant has developed a technology that will revolutionize the monitoring of bacterial contamination levels in water. We offer a truly unique combination of rapid onsite and online analysis of bacterial contamination. BactiQuant technology has been verified by the US-EPA and documented in peer-reviewed scientific publications. BactiQuant technology is currently being used across five continents and improves the quality of life for millions of people around the globe every day. Our business is aligned with four of the UN's Sustainable Development Goals (6, 9, 12 & 14) further highlighting our commitment to the environment. Headquartered in Denmark our customers come from a wide range of industries such as public water utility companies, industries needing water cooling or requiring wastewater treatment, as well as aquaculture.
11 to 50 staff
Bioporto A S
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, clinicians can identify patients potentially at risk of AKI more rapidly than is possible with the current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide. BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit To learn more about our products and their availability in your country, visit bioporto.com or follow our LinkedIn pages: Outside the United States: Within the US: Social Media Community Guidelines: https://bioporto.com/social-media/
11 to 50 staff
Clutch Nutrition
Buy Clutch in Denmark at Wolt Markets (within 30 minutes), matas.dk, helsebixen.dk, nemlig.com and at clutch.dk (both B2C and B2B). Clutch Nutrition - healthy and functional nutrition made easy! Founded by scientists and health professionals. We use our expertise to cut through the jungle that is functional nutrition to bring you the most potent healthy and functional products, based on clinical evidence. We make sure to hand-pick the right ingredients in the right quality, no corners cut. Our first product is a healthy drink for brains based only on natural ingredients that include nootropic herbal extracts, slow-release carbohydrate for sustained energy and dietary fibre. Winner of "Health Innovation" at World Beverage Innovation Awards 2024. Winner of "Best RTD" at World Beverage Innovation Awards 2021. 🥈/ 🥉"Start-Up Award" finalist, NutraIngredients Awards 2021. Winner of "Golden Egg" FoodTech award 2021. Nominated for "Best Health Tech" and "Best Startup" at Nordic Startup Awards 2021. Nominated for the Foodexpo "Startup-Award" 2022. Winner of the food innovation award "The Sharp Knife 2022" by Danish Food Forum. Winner of "Best Natural Brain Stimulation Beverage Brand 2023" by Global Health & Pharma" Patent pending formulation!
1 to 10 staff
Expres2ion Biotechnologies
ExpreS2ion Biotechnologies is a clinical-stage DK based biotech company specialised in the development of new vaccines and immunotherapy products. The company has a clinical Phase discovery platform built around a proprietary recombinant expression system, ExpreS2 TM, developed especially for fast and efficient development and production of complex proteins required for innovative new vaccines, immunotherapy and diagnostics. The system also includes functionally modified glycosylation variants. For the clinical Phase I-stage therapeutic breast cancer vaccine, ES2B-C001, the Company employs a novel plug- & -play capsid virus-like particle (cVLP) platform, that offers competitive advantages in terms of long-term efficacy, safety, stability, and costing. The combination of ExpreS2 and cVLP is also applied in a novel Nipah virus vaccine pipeline project in preclinical stage. The development pipeline also has projects based on the ExpreS2 platform alone, including multiple clinical-stage malaria vaccine projects sponsored by academic partners, as well as novel preclinical-stage influenza vaccines. Since founded in 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with a high number of leading research institutions, biotech and pharma companies, demonstrating superior efficiency and success rates. The cVLP platform resides in its 34%-owned associated company AdaptVac that was founded in 2017. ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary and operational unit of ExpreS2ion Biotech Holding AB, listed on Nasdaq First North Growth Market, Stockholm (Ticker: EXPRS2).
11 to 50 staff
Chreto - A Paradigm Shift In Mab Purification
PROTEIN A CAPTURE OFIMMUNOGLOBULINS IN SOLUTION: SKIP THE PROTEIN A COLUMN Our vision is that the CHRETO Technology™ will - radically improve the process efficiency of downstream processing of large biomolecules - increase yields in existing production, especially IVIG - bring more monoclonal antibody (mAb’s) candidates to testing- speed up initial clinical phases - result in better and more efficient treatment of diseases. We believe that CHRETO’s Protein Purification Technology will bring a true revolution to bio-manufacturing, which has been sought by the industry for decennia. CHRETO was founded in 2010, as a spin out of Novozymes, by the inventor Jan Kyhse-Andersen and Torben Jørgensen to develop and commercialize a novel protein purification technology for bio-manufacturing. The company acquired in 2014 the rights to the original IP related to protein purification technology from Novozymes, DK. A prototype of the technology has been developed and thoroughly tested by industry experts and a leading biopharmaceutical company in Europe during 2014/16. The Technology is expected to be introduced late 2020 How does the CHRETO Technology for mAb purification: The purification process consists of three steps: catch, clean and collect. Catch. The DAP molecule reacts in solution with the feed stream containing the target molecule(s) e.g, an antibody. Clean. Impurities including HCP (host cell proteins) and DNA are removed followed by dissociation of the DAP-antibody complex and capture of DAP to a biotin support. Collect. The purified antibody is collected and the membrane cartridge is discharged. Benefits- Process improvements on 30%- The cost for manufacturing material used in clinical trials is likely to be reduced by a factor of 20. INTERESTED? Contact us for more information: info@chreto.com
1 to 10 staff
Norfalk
Redefining Bio-based surfactants with Biocatalysis – Performance Without Compromise. At NorFalk, we don’t just make bio-based surfactants—we revolutionize them. Unlike conventional bio-based surfactants, our cutting-edge biocatalysis technology delivers consistency, scalability and surfactants of superior performance. Proven Performance: par/better performance compared to current bio-based and biosurfactants on the market. Responsible Innovation: No tropical oil or fossil derived feedstock. Scalable & Cost-Efficient: Designed for large scale applications with real impacts. We’re here to set a new standard—where environmental responsibility and high performance go hand in hand. If you're ready for bio-based surfactants that truly work, let’s talk.
11 to 50 staff
Dorte Egelund Aps
Dorte Egelund ApS is a highly specialized company that offers flexibility and focus on the individual customer. We have the time to go into depth with each application. Our knowledge is based on more than 25 years of experience in selling microbiological and biotechnological solutions. In addition a microbiological education and 12 years of work in both public and private laboratories with microbiology and mammalian cells
1 to 10 staff
Pond Biomaterials
A designer of biomaterials, pond harvest natures own resources and uses advanced technology to create strong and durable biocomposites. pond is a biotech company specialized in making bioresin which has a unique feature – it binds well with naturel fibres. This means the final product is fully biodegradable and ready to be composted when disposed. At pond we are passionate about material awareness and we would like to share this passion with you. Follow us here on LinkedIn and check out our Instagram if you would like to know more about our workday, job openings, material awareness and much more.
11 to 50 staff
Dnasense
Generation of enormous amounts of DNA sequence data has become possible for everyone. However, handling millions of DNA sequences across hundreds of samples is not trivial. At DNASense we use cutting edge DNA sequencing and data analysis to enable effortless sample-to-answer workflows. Our vision is to empower medical doctors, scientists, engineers and technicians working with microbial processes to benefit from the vast possibilities DNA sequencing holds. Enabling true democratisation of modern sequencing techniques supporting microbial identification of bacteria in a multitude of settings e.g. biological waste water treatment plants, drinking water systems, medical implants and more. We provide high throughput bacterial profiling using 16S rRNA gene amplicon sequencing that allows easy comparison of complex microbial communities across many samples. This can tell you the identity of the organisms that are present in the samples and how their abundance changes between the samples over time or between sample types. When you want to know which gene functions your microbes can perform we offer advanced genomic sequencing of pure cultures and complex samples with annotation of genes. We also offer gene expression profiling through transcriptome sequencing and plenty of other custom tailored analyses. We have experts ready to handle any challenge you might have so feel free to contact us by mail at info@dnasense.com or visit our website and we will make sure to find the customized solution that meets your needs.
1 to 10 staff
Dtu Bioengineering
Department of Biotechnology and Biomedicine or in short "DTU Bioengineering" is a scientific community where all members contribute to teaching and research activities that all aim to meet national and international demands for development of sustainable, environmentally friendly, and competitive processes for use within the areas of biotechnology and biomedicine. The particular strength of DTU Bioengineering is that teaching and research activities originate from the integrated use of expertise in disciplines such as molecular biotechnology, biochemistry, microbiology, chemistry, physics, and chemical techniques. The research at DTU Bioengineering covers both basic and applied areas of relevance for biotechnology and biomedicine. Research activities are carried out by all faculty staff at the department. The research is described in three interwoven areas where most, if not all, scientists have activities that fall under two or even all three of the research areas; Microbiology, Biomedicine and Biotechnology.
201 to 500 staff
Ewh Bioproduction Aps
Biological control and IPM in Horticulture, fruit and farmer sector
1 to 10 staff
Glycom A S
Glycom is a biotechnology company with locations in Hørsholm and in Esbjerg, Denmark. We focus on the development, synthesis and commercialization of human milk oligosaccharides (HMOs). HMOs are a group of oligosaccharides which are present in high concentrations in human milk and contribute to many of the wonderful health benefits of mother's milk. In particular, they modulate the infant’s intestinal microbiota to promote the growth of beneficial bacteria and reduce pathogens, protect the infant against infections, and promote development of the infant’s intestine and immune system. HMOs are also believed to contribute to the development of the infant’s brain. They may also be extremely beneficial to older children and adults. Previously commercial use of HMOs has been blocked by lack of availability and high cost. Our breakthrough technologies are changing this paradigm permanently. We have developed efficient microbial fermentation, chemical and enzymatic technologies allowing us to synthesize HMOs. The lead HMOs in our pipeline have robust production technologies now entering industrialisation and we have produced them on large scale under GMP conditions. We and our partners have conducted large, randomized, controlled clinical studies showing safety and tolerance in infants and adults and impact on microbiota. Also, our lead HMOs have been approved for use in foods in Europe and the US. We also have a rich pipeline of other HMOs in early stages of development. We have an active pre-clinical and clinical program to investigate and prove the beneficial properties of HMOs. We are currently expanding our team in production and process development in Esbjerg and R&D in Hørsholm so check out our openings!
51 to 200 staff
Immunaware Aps
immunAware specializes in the biochemistry of MHC class I and II molecules. We offer a large collection of recombinant MHC molecules (>100 allotypes) as monomers, tetramers and easYmers. easYmers are highly active biotinylated MHC molecules which can be loaded with any antigen of interest - a long shelf life allows you to store peptide receptive MHC in your lab and make MHC mono and/or tetramers from day-to-day. Our collection of MHC includes 100+ allotypes covering HLA class I and HLA class II. As services, we also offer measurement of peptide-MHC interactions (e.g. affinity and stability). immunAware is a spin-out from the lab of prof. Søren Buus at the University of Copenhagen, which has >35 years of experience in MHC biochemistry.
1 to 10 staff
Biomassprotein
BiomassProtein™ will organize, finance, build and operate - preferably farmer-owned – sustainable, plant protein factories near strategic customers. Patent pending.
1 to 10 staff
Anapa Biotech A S
Anapa Biotech develops molecular tools enhancing performance of natural nucleicacids (twisted intercalating nucleic acid, TINA) in PCR based assays.
1 to 10 staff
Forward Pharma A S
Forward Pharma A/S was a Danish biopharmaceutical company that from 2005 to 2017 developed a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The company completed a voluntary solvent liquidation in 2025.
1 to 10 staff
Initiator Pharma
Initiator Pharma A/S, a clinical-stage pharma company developing innovative drugs targeting key unmet medical needs within the central and peripheral nervous system. Initiator Pharma is listed on First North Stockholm, Sweden (INIT). Initiator Pharma’s pipeline consists of three clinical programs – the clinical programs IP2018 and pudafensine for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and a neuropathic pain program based on pudafensine. Furthermore, Initiator Pharma has recent announce that the drug candidates, pudafensine and IP2018, have shown significant efficacy in preclinical models for Female Sexual Dysfunction (FSD).
1 to 10 staff
Mipsalus Aps
MipSalus develops treatments for severe, rare amino acid metabolism disorders. First drug in our pipeline is Phelimin for the treatment of Phenylketonuria, PKU. Phelimin is an oral, non-systemic drug that will allow PKU patients to eat normal food and live normal lives. Phelimin has received orphan drug designations from both EMA and FDA. Our medicinal products are based on our proprietary Molecular Imprinted Polymers (MIP) technology platform. We use MIPs to bind specific pathogenic amino acids in the gastrointestinal tract. The name “MipSalus” is a combination of MIP and “Salus” which is the name of the ancient Roman goddess of health and prosperity. In other words; MipSalus’ mission is to use the MIPs technology for healthcare purposes. To ensure optimal efficiency and flexibility MipSalus is a slim core organization supplemented with close collaboration with relevant private subcontractors and universities. MipSalus ApS was founded in 2006 and funded solely by private investors.
1 to 10 staff
Pephexia Therapeutics Aps
Pephexia Therapeutics is a biotechnology company working with the discovery and development of innovative peptide-based pharmacotherapies for an effective and convenient treatment of cachexia and related diseases.
1 to 10 staff
Pisco Group Aps
We believe that industries of today are standing at the brink of an industrial revolution turning the world as we know it upside down. We believe that we can accelerate the aquaculture industry into catching up this evolution! We are here to help fish farmers, technology suppliers and ourselves, move from the burning platform of “status quo” and into the future.
1 to 10 staff
Commit Biologics
Commit Biologics (Commit) is a pioneer in activating the complement system to kill specific target cells, with applications in cancers and autoimmune diseases. Spun out of Aarhus University, and building on more than three decades of research, Commit’s Bispecific Complement Engaging (BiCE™) platform can supercharge a conventional monoclonal antibody to activate the complement system more effectively. This is achieved by combining single domain antibodies that engage C1q, the starting point for the complement activation cascade, with an antibody that binds to a cellular target. The modular approach of the BiCE™ technology can be used to develop therapeutics across multiple tumor-associated antigens and immune cell targets. Complement is a largely untapped aspect of the body’s natural immune system that leverages both the direct cytolytic activity of complement along with its ability to bridge recruitment and activation of both innate and adaptive immune cells – a new approach to killing cells which can be used in combination or on a standalone basis. Commit is backed by major investors including Bioqube Ventures and Novo Holdings, as well as initial funding from the Bio Innovation Institute from Denmark.
11 to 50 staff
